(PDF) Factors Associated With Increased Risk of De Novo or

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection

Clinical Gastroenterology and Hepatology - United Kingdom

doi 10.1016/j.cgh.2018.10.038

Full Text

Open PDF

Abstract

Available in full text

Date

May 1, 2019

Authors

Publisher

Elsevier BV

Related search

Direct-Acting Antiviral Therapy for HCV Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

English

Increased Incidence or Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients Treated With Direct-Acting Antivirals: Myth or Fact?

Expert Review of Anticancer Therapy

Oncology

Pharmacology

2018

English

Imaging Findings of Hepatocellular Carcinoma That Developed After HCV Eradication With Direct-Acting Antivirals

Acta Hepatologica Japonica

Hepatology

2019

English

Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Journal of Hepatocellular Carcinoma

2020

English

Infection Route of Hepatitis C Patients Treated With Direct-Acting Antivirals -To Evaluate the Risk of Reinfection-

Acta Hepatologica Japonica

Hepatology

2017

English

The Risk of Hepatocellular Carcinoma Is Increased in Hepatitis C Virus Patients Treated With Interferonfree Direct-Acting Antiviral-Based Therapy: True or False?

Biomedical Journal of Scientific & Technical Research

2018

English

Direct-Acting Antivirals and Recurrence of Hepatocellular Carcinoma

Liver Transplantation

English

Unexpected Viral Relapses in Hepatitis C Virus-Infected Patients Diagnosed With Hepatocellular Carcinoma During Treatment With Direct-Acting Antivirals

English

The Risk of Early Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C-Infected Patients Treated With Direct-Acting Antivirals With and Without Pegylated Interferon: A Belgian Experience

Journal of Viral Hepatitis

English

Amanote Research

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection

Clinical Gastroenterology and Hepatology - United Kingdom

doi 10.1016/j.cgh.2018.10.038

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Direct-Acting Antiviral Therapy for HCV Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Increased Incidence or Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients Treated With Direct-Acting Antivirals: Myth or Fact?

Imaging Findings of Hepatocellular Carcinoma That Developed After HCV Eradication With Direct-Acting Antivirals

Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Infection Route of Hepatitis C Patients Treated With Direct-Acting Antivirals -To Evaluate the Risk of Reinfection-

The Risk of Hepatocellular Carcinoma Is Increased in Hepatitis C Virus Patients Treated With Interferonfree Direct-Acting Antiviral-Based Therapy: True or False?

Direct-Acting Antivirals and Recurrence of Hepatocellular Carcinoma

Unexpected Viral Relapses in Hepatitis C Virus-Infected Patients Diagnosed With Hepatocellular Carcinoma During Treatment With Direct-Acting Antivirals

The Risk of Early Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C-Infected Patients Treated With Direct-Acting Antivirals With and Without Pegylated Interferon: A Belgian Experience